LYEL Stock Summary and Trading Ideas (Lyell Immunopharma | NASDAQ:LYEL)

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.

As of March 11, 2026, LYEL stock price declined to $25.14 with 137,743 million shares trading.

LYEL has a beta of 1.57, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.08 to the broad based SPY ETF.

LYEL has a market cap of $534.07 million. This is considered a Small Cap stock.

In the last 3 years, LYEL traded as high as $79.40 and as low as $7.65.

The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, VXF, SCHA, IBB, DWAS.

LYEL has outperformed the market in the last year with a price return of +84.5% while the SPY ETF gained +21.9%. However, in the short term, LYEL had mixed performance relative to the market. It has underperformed in the last 3 months, returning -19.6% vs -1.3% return in SPY. But in the last 2 weeks, LYEL shares have fared better than the market returning +9.0% compared to SPY -1.6%.

LYEL support price is $23.68 and resistance is $27.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.